J Hypertens. 2012 Sep;30(9):1681-9. doi: 10.1097/HJH.0b013e3283569a9c.

An update on biomarkers of heart failure in hypertensive patients.

Journal of hypertension

Anna Gluba, Agata Bielecka-Dabrowa, Agata Bielecka, Dimitri P Mikhailidis, Nathan D Wong, Stanley S Franklin, Jacek Rysz, Maciej Banach

PMID: 22828089 DOI: 10.1097/HJH.0b013e3283569a9c

Abstract

Biomarkers should have high sensitivity, specificity, reproducibility, be cost-effective, and provide incremental predictive or diagnostic utility over standard risk factors or tests. Despite numerous studies investigating biomarkers in heart failure (HF), there are only a few that predict HF in hypertensive patients. This article summarizes data from numerous studies concerning possible biomarkers of HF in hypertensive patients such as: serum uric acid (SUA), interleukins, monocyte chemoattractant protein one (MCP-1), cardiotrophin-1 (CT-1), carboxy-terminal propeptide of procollagen type I (PICP), type I collagen telopeptide (CITP) and N-terminal propeptide of type III procollagen (PIIINP), metalloproteinases (MMPs), B-type natriuretic peptide (BNP) and its derivatives, glycoprotein CA125 and cystatin C. Early detection of patients of increased risk of hypertensive heart disease may result in early implementation of effective preventive strategies. Therefore, there is need to identify newer biomarkers, if they can improve risk prediction, identifying patients, in which earlier or more aggressive intervention will improve clinical outcomes.

MeSH terms

• Heart Failure / metabolism*
• Humans
• Hypertension / metabolism*

Publication Types

• Journal Article
• Review